Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)

Clinical trial NCT05291390 · UNKNOWN

Trial details

NCT number: NCT05291390
Sponsor: Armaceutica, Inc.
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia (AML)Acute Lymphoblastic Leukemia (ALL)

Start date: 2022-11-21
Primary completion: 2024-02-01
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.